Crowdonomics
All companies

ClearLight Biotechnologies, Inc.

Operating

Sunnyvale, CA

Latest valuation
—
No round has disclosed a priced valuation or cap.
Total raised
$0
Across 1 round since 2021
Latest share price
$12.00
Reg A Offering (2021) offering price

Financials

FY2020 · from SEC filings · hover any figure for its source
$30K
−$680K
2020
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
Income statement
Revenue
$29,874
Cost of goods sold
$157,760
Gross margin
-428%
Net income
-$680,461
Balance sheet
Cash
$718,333
Accounts receivable
$17,595
Total assets
$2,072,588
Long-term debt
$0
Total liabilities
$500,080
Other
Headcount
5

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Fundraising history

Reg A Offering (2021)ClosedReg A+ · Equity
Raised $0 / $240K

SEC filings

  • Form 1-A/ADec 2, 20210001062993-21-012019
    EDGAR
  • Form 1-ANov 19, 20210001062993-21-011161
    EDGAR
Source: SEC EDGARCIK 0001656367DEShare price $12.00Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.